BioLineRx (BLRX) Q3 2024 earnings summary

Executive summary

• Entered exclusive license agreement with Ayrmid Limited (Gamida Cell) for motixafortide (APHEXDA), excluding solid tumors and Asia, with $10M upfront, $87M in milestones, and 18–23% royalties.

• Received $9M equity investment from Highbridge Capital, supporting pipeline expansion and enabling significant debt repayment and restructuring with BlackRock.

• Transitioned U.S. commercial operations to Gamida Cell, reducing annual cash burn by over 70% effective January 2025 and extending cash runway into 2026.

• Restructured and reduced long-term debt by $16.5M, with remaining balance payable over three years at 9.5% interest.

• Refocused on drug development, especially in oncology and rare diseases, with plans to in-license one asset in 2025 and another in 2026.

Financial highlights

• Q3 2024 revenue was $4.9M, compared to no revenue in Q3 2023; $3.2M from Gloria Biosciences license and $1.7M from APHEXDA U.S. sales.

• Cost of revenue was $0.8M, mainly from amortization, royalties, and cost of goods sold.

• R&D expenses were $2.6M, down from $2.7M year-over-year, due to lower costs from terminated programs and reduced payroll.

• Sales and marketing expenses dropped to $5.5M from $8.1M, reflecting lower commercialization costs.

• Net loss for Q3 2024 was $5.8M, a significant improvement from $16M in Q3 2023.

• Cash and equivalents stood at $29.2M as of September 30, 2024; post-transaction, expected to be ~$20M, sufficient to fund operations into 2026.

Outlook and guidance

• Annual operational expenses expected to decline by over 70% starting January 2025.

• Cash position after recent transactions projected to fund operations into 2026 under current plans.

• Plans to evaluate and in-license one new early-stage clinical asset in 2025 and another in 2026.

• Anticipates adding three new clinical trial sites to the Phase 2b PDAC trial in the next two quarters, with interim data expected in 2026.

• Expects first revenues from China region in 2025 via Gloria Biosciences partnership.